Target intelligence / Profile preview

Solute carrier family 52 member 2 (Riboflavin transporter 2) (SLC52A2)

Target
SLC52A2
Molecular classification
Transporter (solute carrier family protein), Riboflavin transporter
01

Overview

Solute carrier family 52 member 2, commonly known as **Riboflavin transporter 2 (SLC52A2)**, is a cellular membrane protein highly expressed in the central and peripheral nervous system. It mediates the uptake and intracellular transport of riboflavin (vitamin B2), which is required for the synthesis of FMN and FAD, coenzymes involved in cellular energy metabolism and the breakdown of carbohydrates, fats, and proteins. Mutations in the SLC52A2 gene cause riboflavin transporter deficiency neuronopathy (RTD type 2), a progressive neurodegenerative disorder manifesting as sensorimotor neuropathy, hearing loss, muscle weakness, and respiratory compromise. The primary therapeutic approach is high-dose oral riboflavin, which can arrest or reverse symptoms if started promptly. Experimental gene therapy approaches are also being investigated to restore transporter function in affected neurons[1][2][3][4].

Other names
RFVT2RFT3hRFT3BVVLS2GPR172APAR1D15Ertd747eFLJ11856Riboflavin transporter 3Porcine endogenous retrovirus A receptor 1 / HuPAR-1 / PERV-A receptor 1
02

Mechanism of action

Supplementation restores required riboflavin intracellular concentration, rescuing coenzyme (FMN, FAD) production and neuronal function. Experimental: Gene therapy (AAV9-SLC52A2 vector) to restore functional transporter in affected neurons

03

Biological functions

Riboflavin (vitamin B2) transport across cell membranesVitamin absorption in cells, especially neural tissueDelivery of riboflavin for coenzyme synthesis (FMN, FAD)Cellular energy metabolism and biogenesis
04

Disease associations

Neurodegenerative disease (Brown-Vialetto-Van Laere syndrome)Riboflavin transporter deficiency neuronopathy (formerly Fazio-Londe disease, Brown-Vialetto-Van Laere syndrome)Other: Riboflavin transporter deficiency (RTD type 2)
05

Safety considerations

Risk of progressive neurological decline if untreatedNo major safety concerns with riboflavin supplementation, but gene therapy risks are theoretical and under research
06

Interacting drugs

Riboflavin

1 more in the full profile.

07

Biomarkers

Low serum flavin (riboflavin, FMN/FAD) levelsAbnormal acylcarnitine profileUrine organic acids (abnormal profile)Genetic detection of SLC52A2 mutations

Beyond the preview

Go deeper on Solute carrier family 52 member 2 (Riboflavin transporter 2) (SLC52A2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 52 member 2 (Riboflavin transporter 2) (SLC52A2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call